Cargando…

Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria

INTRODUCTION: Primary membranous nephropathy (PMN) is one common cause of end-stage kidney disease. There is no optimal treatment for PMN patients with sub-nephrotic proteinuria currently. Tripterygium wilfordii polyglycoside (TWG) is a widely used traditional medicine in China and has been used to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yuanyuan, Guo, Ningning, Wang, Jin, Wang, Ruiqiang, Tang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081316/ https://www.ncbi.nlm.nih.gov/pubmed/33904354 http://dx.doi.org/10.1080/0886022X.2021.1918555

Ejemplares similares

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Calcineurin inhibitor therapy in combination with Tripterygium wilfordii polyglycoside tablets for idiopathic membranous nephropathy: A retrospective clinical observation
por: Gao, Ying, et al.
Publicado: (2021)

Effect of Tripterygium Wilfordii Polyglycoside on Experimental Prostatitis Caused by Ureaplasma Urealyticum in Rats
por: Shan, Pingnan, et al.
Publicado: (2016)

Meta-Analysis of Clinical Efficacy and Safety of Tripterygium wilfordii Polyglycosides Tablets in the Treatment of Chronic Kidney Disease
por: Guo, Yan-Li, et al.
Publicado: (2021)

Efficacy and safety of Tripterygium wilfordii polyglycosides for diabetic kidney disease: an overview of systematic reviews and meta-analyses
por: Wang, Ying, et al.
Publicado: (2022)

Tripterygium wilfordii Polyglycoside Ameliorated TNBS-Induced Colitis in Rats via Regulating Th17/Treg Balance in Intestinal Mucosa
por: Zhang, Cui, et al.
Publicado: (2021)

Mechanism of action of Tripterygium wilfordii for treatment of idiopathic membranous nephropathy based on network pharmacology
por: Shi, Honghong, et al.
Publicado: (2022)

The Active Compounds and Therapeutic Target of Tripterygium wilfordii Hook. f. in Attenuating Proteinuria in Diabetic Nephropathy: A Review
por: Liu, Peng, et al.
Publicado: (2021)

Study of the Active Components and Molecular Mechanism of Tripterygium wilfordii in the Treatment of Diabetic Nephropathy
por: Wang, Lin, et al.
Publicado: (2021)

Guilu-Erxian-Glue alleviates Tripterygium wilfordii polyglycoside-induced oligoasthenospermia in rats by resisting ferroptosis via the Keap1/Nrf2/GPX4 signaling pathway
por: Ding, Jin, et al.
Publicado: (2023)

Effect of Cordyceps sinensis and Tripterygium wilfordii polyglycosidium on podocytes in rats with diabetic nephropathy
por: HAO, LI, et al.
Publicado: (2014)

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2023)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
por: Lin, Na, et al.
Publicado: (2021)

Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis
por: Chen, Ming, et al.
Publicado: (2022)

Investigating the Catalytic Activity of Glycosyltransferase on Quercetin from Tripterygium wilfordii
por: Gao, Jie, et al.
Publicado: (2020)

Mechanistic analysis for the origin of diverse diterpenes in Tripterygium wilfordii
por: Tu, Lichan, et al.
Publicado: (2022)

Tripterygium wilfordii multiglycosides combined with prednisone in the treatment of idiopathic membranous nephropathy: A protocol for a systematic review and meta-analysis
por: Jin, Yuxia, et al.
Publicado: (2020)

Efficacy and safety of tripterygium wilfordii multiglycosides in idiopathic membranous nephropathy: Protocol for an open-label randomized controlled clinical trial
por: Geng, Chanyu, et al.
Publicado: (2022)

Based on Network Pharmacology Tools to Investigate the Mechanism of Tripterygium wilfordii Against IgA Nephropathy
por: Xia, Ming, et al.
Publicado: (2021)

Combination of Tripterygium wilfordii Hook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease
por: Ma, Ruixia, et al.
Publicado: (2015)

The genome of Tripterygium wilfordii and characterization of the celastrol biosynthesis pathway
por: Pei, Tianlin, et al.
Publicado: (2021)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Glomerulosclerosis is a prognostic risk factor in patients with membranous nephropathy and non-nephrotic proteinuria
por: Sun, Jing, et al.
Publicado: (2023)

Retracted: Efficacy and Safety of Glycosides of Tripterygium wilfordii Combined with Renin-Angiotensin System in the Treatment of IgA Nephropathy: A Systematic Review and Meta-Analysis
por: International, Emergency Medicine
Publicado: (2023)

The complete chloroplast genome of Tripterygium wilfordii Hook. f. (Celastraceae)
por: Zhong, Yuan, et al.
Publicado: (2022)

Primary IgA nephropathy with nephrotic-range proteinuria in Chinese children
por: Zhao, Jing-Li, et al.
Publicado: (2021)

Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy: A protocol for meta-analysis
por: Ma, Chang-e, et al.
Publicado: (2021)

Tripterygium wilfordii Hook F Treatment for Stage IV Diabetic Nephropathy: Protocol for a Prospective, Randomized Controlled Trial
por: Lengnan, Xu, et al.
Publicado: (2020)

Immunosuppressive Sesquiterpene Pyridine Alkaloids from Tripterygium wilfordii Hook. f.
por: Wang, Yadan, et al.
Publicado: (2022)

Molecular Cloning and Characterisation of Farnesyl Pyrophosphate Synthase from Tripterygium wilfordii
por: Zhao, Yu-Jun, et al.
Publicado: (2015)

Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial
por: Ge, Yongchun, et al.
Publicado: (2013)

The effect and safety of low-dose Tripterygium wilfordii in patients with type 2 diabetic nephropathy: A meta-analysis
por: Chen, Yixuan, et al.
Publicado: (2022)

Native Endophytes of Tripterygium wilfordii-Mediated Biotransformation Reduces Toxicity of Celastrol
por: Ma, Ping-yang, et al.
Publicado: (2022)

Exploration of the Mechanism of Tripterygium Wilfordii in the Treatment of Myocardial Fibrosis Based on Network Pharmacology and Molecular Docking
por: Ming, Yang, et al.
Publicado: (2023)

Tripterygium Wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy
por: Li, Huining, et al.
Publicado: (2017)

A PRISMA-compliant systematic review and network meta-analysis on the efficacy between different regimens based on Tripterygium wilfordii Hook F in patients with primary nephrotic syndrome
por: Wang, Xin-bin, et al.
Publicado: (2018)

Male Germ Cell Apoptosis and Epigenetic Histone Modification Induced by Tripterygium wilfordii Hook F
por: Xiong, Ji, et al.
Publicado: (2011)

Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii
por: Ji, Wei, et al.
Publicado: (2010)

New 18(4→3)-Abeo-Abietanoids from Tripterygium wilfordii
por: Ni, Lin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c8iuqghmcgdv7fgl842mfrfv3e